Skip to Content
Merck
CN

D2255000

Dinoprost trometamol

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Prostaglandin F2α tris salt, (5Z,9α,11α,13E,15S)-9,11,15-Trihydroxyprosta-5,13-dienoic acid tris salt, PGF2α−Tris

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C20H34O5 · C4H11NO3
CAS Number:
38562-01-5
Molecular Weight:
475.62
UNSPSC Code:
41116107
NACRES:
NA.24
PubChem Substance ID:
329798735
MDL number:
MFCD00077863
Beilstein/REAXYS Number:
4087514

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Dinoprost trometamol, European Pharmacopoeia (EP) Reference Standard

InChI key

IYGXEHDCSOYNKY-RZHHZEQLSA-N

SMILES string

NC(CO)(CO)CO.[H][C@]1(C\C=C/CCCC(O)=O)[C@@H](O)C[C@@H](O)[C@]1([H])\C=C\[C@@H](O)CCCCC

InChI

1S/C20H34O5.C4H11NO3/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25;5-4(1-6,2-7)3-8/h4,7,12-13,15-19,21-23H,2-3,5-6,8-11,14H2,1H3,(H,24,25);6-8H,1-3,5H2/b7-4-,13-12+;/t15-,16+,17+,18-,19+;/m0./s1

grade

pharmaceutical primary standard

API family

dinoprost

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

Gene Information

human ... PTGFR(5737)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Application

Dinoprost trometamol EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Luteolytic prostaglandin that induces parturition. Potent vasoconstrictor of pulmonary, coronary, and cerebral arteriole beds.
Luteolytic prostaglandin that induces parturition. Potent vasoconstrictor of pulmonary, coronary, and cerebral arteriole beds. A positive feedback loop between endometrial PG F2α and luteal oxytocin is responsible for completion of luteolysis.
Luteolytic prostaglandin that induces parturition. Potent vasoconstrictor of pulmonary, coronary, and cerebral arteriole beds. Also stimulates contraction of smooth muscle, such as in bronchi, with possible involvement in asthma. This effect is at least partially mediated through tachykinin release.

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Other Notes

Sales restrictions may apply.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

pictograms

Health hazardExclamation mark
GHS08,GHS07

signalword

Danger

Hazard Classifications

Acute Tox. 4 Oral - Repr. 1B

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk

WGK 3

Regulatory Information

监管及禁止进口产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

If you need assistance, please contact Customer Support

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

S N Johnson et al.
Theriogenology, 55(9), 1787-1795 (2001-06-21)
Estrous response and pregnancy rates are decreased for cows given Syncro-Mate-B (SMB) during metestrus (Day 1 to 5 of an estrous cycle). Data indicate these decreases are due, in part, to retention of a functional corpus luteum (CL). Our objective
J R Pursley et al.
Theriogenology, 78(4), 823-829 (2012-05-26)
Using two PGF(2α) treatments 14 days apart as a way to enhance estrus detection rate following the 2nd treatment is a reproductive management tool that continues to be used on large dairy farms. In one study, in cows with a
M González-Lozano et al.
Journal of veterinary pharmacology and therapeutics, 33(1), 28-34 (2010-05-07)
The aims of the study were to characterize the uterine activity in sows treated with vetrabutin chlorhydrate (VC), an uterotonic and muscle-tropic drug during farrowing, and to measure the effects of the drug on piglet neonatal viability. The experiment involved
J P N Martins et al.
Journal of dairy science, 94(6), 2806-2814 (2011-05-25)
The probability of a pregnancy decreases substantially in lactating dairy cows treated with Ovsynch if luteolysis is delayed or incomplete. Two PGF(2α) products are currently approved in the United States for luteolysis in lactating dairy cattle, dinoprost tromethamine and cloprostenol
Ellen Bronson et al.
Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians, 36(4), 716-718 (2007-02-23)
A 4-yr-old female golden lion tamarin (Leontopithecus rosalia) had placental retention after delivery of a stillborn fetus. Conservative therapy with oxytocin and dinoprost tromethamine did not result in placental expulsion and ovariohysterectomy was performed. Placental retention is a rare condition
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service